Science156d left
Will the FDA approve MDMA for PTSD?
Make a prediction2 votes
Resolution
Criteria
If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes.
Source
Kalshi (kalshi.com)
Context
The FDA has been reviewing the use of MDMA for treating PTSD, with phase III clinical trials showing promising results. Researchers have been studying the therapeutic potential of MDMA, also known as Ecstasy, for several years. The FDA's decision is highly anticipated by the medical community.
Recent News
- FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times
Psychiatric Times
- What the VA’s New MDMA-Assisted Therapy Trial Signals for Providers - Behavioral Health Business
Behavioral Health Business
- One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect - Psychedelic Alpha
Psychedelic Alpha
Closes 156d left
Resolves Jan 1, 2032, 3:00 PM UTC
Discussion
Sign in to join the discussion.